Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
about
Targeting the TAM Receptors in LeukemiaMolecular Imaging of Pancreatic Cancer with Antibodies.Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaIntegrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairsGlobal phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Activation of multiple growth factor signalling pathways is frequent in meningiomas.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Carcinogenesis-relevant biological events in the pathophysiology of the efferocytosis phenomenon.Targeting Gas6/TAM in cancer cells and tumor microenvironment.Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?AXL phosphorylates and up-regulates TNS2 and its implications in IRS-1-associated metabolism in cancer cells
P2860
Q28078654-C83D4F57-3A05-413E-9E53-6157A1DEA2ACQ30393523-9C4B18C2-5FDC-44A9-B919-1884ECE3C5D1Q34390266-AB687EF7-1B9C-44D8-9591-1EAA421521D0Q34439798-779D2349-6F74-477D-9603-717314DE0691Q36214760-FBA857F3-0A8F-4975-BD51-2A1B45721E48Q36287092-9B51BA69-4F4D-4ED0-8357-34141F2226C9Q36485634-9D2B048C-8A60-4D5B-BB19-86673AE93AACQ36557240-2990DCB4-D6F6-4B4A-A7FD-4EFA65D90C7FQ38214511-890CFFA4-D92F-4CEB-80AC-52A406C8BAB5Q38771601-4DC08080-24E5-4423-8971-44BC1C9A74A3Q38821208-DD05E971-65C4-4741-B82A-208AC69D58FBQ38835745-DF24ABC2-16FE-4C45-8353-58F5D27C3FBAQ38944293-FAA8A287-0B7E-4074-8C25-C381F19B845AQ39157476-480A4460-181A-4898-B11D-8B15AC06DA2FQ39160959-73A100A9-00FA-47B3-9079-65B0728711FFQ47109220-57B87687-C2DC-4868-8F40-C1F4A29443CBQ47111434-075D74EF-F5E9-4D73-B81E-71037EBBA60CQ47701436-C2AE8BC8-599C-4C79-A68B-BE12D039FF2BQ49587589-9CE037FD-1B15-416C-9A65-D333ECA03BE1Q49737040-0A422895-7496-41D8-937C-F10B8D13CA6DQ51146366-76C5C07E-B8B9-48B8-91C2-732E66F7D900Q53509565-E648109D-92D6-41D0-9555-E4C68EEB1322Q54297620-9283F00A-4252-4C4D-B234-140F737271A5Q59136222-87AC30CF-C401-4D20-A162-8C1047CE42D0
P2860
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@en
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@nl
type
label
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@en
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@nl
prefLabel
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@en
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Preclinical validation of AXL ...... ncreatic cancer immunotherapy.
@en
P2093
A Pèlegrin
C Larbouret
J-M Pasquet
M Neiveyans
M Pugnière
P2860
P2888
P304
P356
10.1038/ONC.2013.487
P407
P577
2013-11-18T00:00:00Z